PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för binimetinib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

21 hits

Bibliografisk träff 2019-10-09

Binimetinib in heavily pretreated patients with NRAS-mutant melanoma with brain metastases.

Goldinger SM, Valeska Matter A, Urner-Bloch U, Narainsing J, Micaletto S, Blume I, Mangana J, Dummer R.

Br J Dermatol · letter; research support, non-u.s. gov't · DOI 10.1111/bjd.18449

Bibliografisk träff 2019-09-13

Binimetinib plus encorafenib for metastatic melanoma.

Författaruppgift saknas

Aust Prescr · review-article; review; journal article · DOI 10.18773/austprescr.2019.057

Bibliografisk träff 2019-08-19

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.

Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Sileni VC, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Gollerkeri A, Pickard MD, Robert C.

Eur J Cancer · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.ejca.2019.07.016

Bibliografisk träff 2019-08-08

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

Bardia A, Gounder M, Rodon J, Janku F, Lolkema MP, Stephenson JJ, Bedard PL, Schuler M, Sessa C, LoRusso P, Thomas M, Maacke H, Evans H, Sun Y, Tan DSW.

Oncologist · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1634/theoncologist.2019-0297

Bibliografisk träff 2019-07-17

Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study.

Kim JW, Lee KH, Kim JW, Suh KJ, Nam AR, Bang JH, Bang YJ, Oh DY.

Br J Cancer · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1038/s41416-019-0523-5

Bibliografisk träff 2019-06-18

A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor.

Rosenbaum E, Kelly C, D'Angelo SP, Dickson MA, Gounder M, Keohan ML, Movva S, Condy M, Adamson T, Mcfadyen CR, Antonescu CR, Hwang S, Singer S, Qin LX, Tap WD, Chi P.

Oncologist · other; research support, non-u.s. gov't; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1634/theoncologist.2019-0418

Bibliografisk träff 2019-05-25

Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.

Sakakibara K, Tsujioka T, Kida JI, Kurozumi N, Nakahara T, Suemori SI, Kitanaka A, Arao Y, Tohyama K.

Int J Hematol · journal article · DOI 10.1007/s12185-019-02667-1

Bibliografisk träff 2019-04-01

Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.

Rose AAN.

Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2019.55.4.2958476

Bibliografisk träff 2019-03-05

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced <i>NRAS</i>- or <i>BRAF</i>-mutated melanoma.

van Herpen CML, Agarwala SS, Hauschild A, Berking C, Beck JT, Schadendorf D, Jansen R, Queirolo P, Ascierto PA, Blank CU, Heinrich MC, Pal RR, Derti A, Antona V, Nauwelaerts H, Zubel A, Dummer R.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.26753

Bibliografisk träff 2019-01-24

Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.

Trojaniello C, Festino L, Vanella V, Ascierto PA.

Expert Rev Clin Pharmacol · comparative study; review; journal article · DOI 10.1080/17512433.2019.1570847

Bibliografisk träff 2019-01-16

Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment.

Shen Y, Crassini K, Sandhu S, Fatima N, Christopherson RI, Mulligan SP, Best OG.

Leuk Lymphoma · journal article · DOI 10.1080/10428194.2018.1542148

Bibliografisk träff 2018-12-20

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.

Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F.

Clin Lymphoma Myeloma Leuk · clinical trial, phase ii; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.clml.2018.12.009

Bibliografisk träff 2018-08-01

Encorafenib and Binimetinib: First Global Approvals.

Shirley M.

Drugs · review; journal article · DOI 10.1007/s40265-018-0963-x

Bibliografisk träff 2018-05-24

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment.

Han C, Bellone S, Zammataro L, Schwartz PE, Santin AD.

Gynecol Oncol Rep · journal article; case reports; case-report · DOI 10.1016/j.gore.2018.05.011

Bibliografisk träff 2018-05-22

Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.

Finn RS, Ahn DH, Javle MM, Tan BR, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS.

Invest New Drugs · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s10637-018-0600-2

Bibliografisk träff 2017-09-08

Binimetinib for the treatment of NRAS-mutant melanoma.

Queirolo P, Spagnolo F.

Expert Rev Anticancer Ther · review; journal article · DOI 10.1080/14737140.2017.1374177

Bibliografisk träff 2017-06-07

A review of binimetinib for the treatment of mutant cutaneous melanoma.

Koelblinger P, Dornbierer J, Dummer R.

Future Oncol · review; journal article · DOI 10.2217/fon-2017-0170

Bibliografisk träff 2017-04-12

An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.

Rousset M, Titier K, Bouchet S, Dutriaux C, Pham-Ledard A, Prey S, Canal-Raffin M, Molimard M.

Clin Chim Acta · journal article · DOI 10.1016/j.cca.2017.04.009

Bibliografisk träff 2017-02-02

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.

Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A.

Br J Cancer · research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1038/bjc.2017.10

Bibliografisk träff 2016-04-12

A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.

Watanabe K, Otsu S, Hirashima Y, Morinaga R, Nishikawa K, Hisamatsu Y, Shimokata T, Inada-Inoue M, Shibata T, Takeuchi H, Watanabe T, Tokushige K, Maacke H, Shiaro K, Ando Y.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s00280-016-3019-5

Bibliografisk träff 2013-02-13

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R.

Lancet Oncol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1016/s1470-2045(13)70024-x